MYGN

Myriad Genetics Inc. 10-Q Summary: Period Ended December 31, 2007

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2007, and the six months ended on that date. Myriad Genetics, Inc. is a biotechnology company operating in three segments: research, molecular diagnostics, and drug development. The company focuses on the genetic basis of human disease to develop therapeutic products and molecular diagnostic tests. As of January 31, 2008, the company had 43,413,174 shares of common stock outstanding.

Key Financial Metrics

Liquidity and Debt: The company reported no long-term debt. Total current liabilities were $34.89 million. Net cash used in operating activities for the six months ended December 31, 2007, was $12.5 million. Net cash used in investing activities was $31.3 million, primarily due to purchases of marketable securities and capital expenditures. Financing activities provided $15.0 million, largely from stock option exercises.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 53% year-over-year for the three months ended December 31, 2007 ($56.7M vs. $37.1M) and 49% for the six-month period ($105.0M vs. $70.7M). Molecular diagnostic revenue drove this growth, rising 55% and 52% respectively.
• Expense Increases: Selling, general, and administrative (SG&A) expenses surged 88% for the quarter ($30.5M vs. $16.2M) and 87% for the six months ($57.0M vs. $30.4M). This was attributed to increased sales commissions, a direct-to-consumer advertising campaign for BRACAnalysis, and higher bad debt expense ($1.9M increase for the quarter).
• Profitability: While the net loss narrowed compared to the prior year periods (from $(8.8M) to $(5.1M) for the quarter), the company remains unprofitable with an accumulated deficit of $265.5 million.
• Share-Based Compensation: Expense increased significantly due to new grants and plan amendments, rising from $1.7M to $3.8M for the quarter.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and the launch of new diagnostic products. The company believes its existing capital resources are sufficient to maintain operations for at least the next two years.

Clinical Pipeline:

• Flurizan (Alzheimer's): Two Phase 3 trials are ongoing; the U.S. trial is expected to conclude in March 2008 with results anticipated by June 2008.
• Azixa (Brain Tumors): Three Phase 2 trials are in progress.
• Vivecon (AIDS) & MPC-2130 (Hematologic Cancers): In Phase 1 testing.

Risks and Contingencies:

• Success depends heavily on the results of clinical trials, particularly for Flurizan.
• Regulatory approval is required for all therapeutic candidates.
• Competition in molecular diagnostics and pharmaceuticals.
• Intellectual property protection and potential patent infringement claims.
• Reliance on a limited number of molecular diagnostic products for revenue.

Key Facts for Investor Verification

• Cash Burn Rate: Verify the sustainability of the $12.5 million operating cash outflow over six months against the $303.5 million total liquid assets (cash + marketable securities).
• Flurizan Trial Timeline: Confirm the status of the Phase 3 Alzheimer's trial, as results expected in mid-2008 are critical for future valuation.
• SG&A Efficiency: Monitor if the sharp increase in SG&A (driven by marketing and bad debt) stabilizes as revenue growth continues.
• Bad Debt Exposure: Review the allowance for doubtful accounts, which increased to $3.65 million, reflecting higher bad debt expense tied to sales growth.
• Capital Needs: Assess the likelihood of future equity dilution given the company's statement that it may access capital markets if conditions are favorable.